For more update - Follow MERIL social media pages below
親愛的客戶/同業先進/協力廠商 鈞鑒 :
電話號碼 : (02)8666-0077
傳真號碼 : (02)8666-5095
公司地址 : 23159新北市新店區安興路125之12號5樓
Stents are the mainstay of endovascular revascularization in peripheral interventions, but metal in stents can cause re-occlusions to occur in the long run. One answer is to use a scaffold; it can act like a stent and scaffold the segment but is later resorbed, preventing re-stenosis.
Investigator Vimal Someshwar outlines 30-day findings on stent thrombosis from a study into the performance of the Credence BtK bioresorbable scaffold, a bioresorbable sirolimus-eluting stent for the intra-popliteal artery. Watch as he explains the chemistry behind the hybrid model, which consists of a closed cell at the ends and an open cell design along the shaft of the stent, and summarises the clinical criteria for inclusion in the study.
V. Someshwar sees a “bright future” for this device; learn more about the data on wound healing and target lesion revascularization, and discover what his prediction is based upon…
First-generation scaffolds were large devices 150 µm thick and had several limitations as a result; apart from being difficult to use with poor deliverability, one of their biggest deficiencies was safety, with high scaffold thrombosis rates. At EuroPCR 2018, investigator Ashok Seth presented findings on the MeRes100, the first ever bioresorbable scaffold with a strut thickness of 100 µm. He describes the “fascinating characteristics” and “unique architecture” of the scaffold and outlines the advantages conferred by its PLLA backbone with a sirolimus-eluting coating and its availability in a variety of sizes. Discover his thoughts on the 2-year clinical optimized computed tomography (OCT) and intravascular ultrasound (IVUS) first-in-human data on MeRes100 in 108 patients with coronary artery disease. The “extremely favorable” and “encouraging” results will form the basis of a pivotal 2000-patient, randomized study comparing MeRes100 to a Xience everolimus-eluting stent that is due to commence later this year. Watch to learn more…
Watch as investigator Rao Ravinder Singh summarises the findings from the MyVal study, which he presented at EuroPCR 2018. The first-in-man study reveals 30-day clinical and echocardiographic results of a next-generation balloon-expandable transcatheter aortic valve replacement (TAVR) system in 30 patients with severe stenosis of the native aortic valve. R.R. Singh outlines the technology of the valve, and its performance immediately post-procedure and at 30 days in relation to mean gradient, pacemaker rate, and mild, moderate, and severe paravalvular leak. Find out his conclusions on its safety in these patients…
Please do joing us for a Refreshing Scientific Discussion at
Meril Booth #F10, Level-1.